questionText: To ask the Secretary of State for Health and Social Care, with reference to the submission by NHS England to NICE of Form ID6262: Nirmatrelvir plus ritonavir for treating COVID-19 (Partial Rapid Review of TA878), what assessment she has made of the potential merits of NHS England’s request for a 12-month delay to access to Paxlovid for some clinically vulnerable patients.
answerText: The Department recognises that implementation of the updated National Institute for Health and Care Excellence (NICE) recommendations on nirmatrelvir plus ritonavir (Paxlovid) within the standard three-month timescale that applies to NICE’s recommendation...
heading: Nirmatrelvir/ritonavir